Novartis vaccine Bexsero combats meningitis

Novartis ($NVS) is reporting its vaccine Bexsero stimulated an immune response against three strains of the meningococcus B bacterium. An approval would open the door to jabs that would combat the full slate of serogroups that are the primary cause of meningococcal disease around the world. The CDC's Amanda Cohn and Nancy Messonnier called it a "major step forward." Story

Suggested Articles

Relay Therapeutics has pulled off a major upsized IPO worth $400 million to propel a pipeline of treatments aiming at previously undruggable targets.

The series C follows phase 1b data on the brain cancer treatment that persuaded existing investors including HP WILD to commit more cash.

Ex-Gilead CSO Norbert Bischofberger has struck a deal to buy a portfolio of spleen tyrosine kinase inhibitors from his former employer.